The strategic collaboration will see the Hong-Kong-headquartered contract development and manufacturing organisation (CDMO) make antigen-focused therapies.
“This collaboration is expected to introduce the world-class life-saving biologics to the Chinese market, and then benefit patients around the world,” said WuXi BioLogics CEO Chris Chen in a statement.
WuXi BioLogics’ manufacturing plant – located 100km west of Shanghai – consists of two 1,000L single-use bioreactors, and 14 2,000L fed-batch cell culture disposable vessles supplied by vendor Thermo Fisher.
Three months ago the CDMO announced it had initiated current good manufacturing practice (cGMP) production at the site.
At the time, WuXi BioLogics told told Biopharma-Reporter the facility’s 30,000L capacity was already “mostly filled.”